£140 million innovation investment boost following fundraising by Imperial Innovations: Pharmaleaders www.pharmaleaders.co.in

SUVEN PARTNERS WITH J P MORGAN HEALTHCARE CONFERENCE 2011

The global top 10 drug discovery technologies market is expected to be around $ 30.8 billion in 2010 and estimated to reach $ 54 billion mark in 2015, growing at a CAGR of 11.9 % from 2010-2015. £140 million innovation investment boost following fundraising by Imperial Innovations: Pharmaleaders www.pharmaleaders.co.in

Delhi: Jan 11, 2011 – The global top 10 drug discovery technologies market is expected to be around $ 30.8 billion in 2010 and estimated to reach $ 54 billion mark in 2015, growing at a CAGR of 11.9 % from 2010-2015. The market for high throughput screening accounts for the largest share with approximately 33% of the entire market for top 10 drug discovery technologies. This huge market share is mainly due to the increasing applications of cell based assays and robotics in the parallel screening of compounds. The top 10 drug discovery technologies play a vital role in the growth of the entire pharmaceutical industry as they are the key contributors in the swift introduction of blockbusters and innovative drugs, which is the most important aspect for the pharmaceutical companies. The applications of these technologies in the introduction of drugs for diverse diseases such as cancer, CVD, CNS disorders such as Parkinson’s and Alzheimer’s and other serious chronic diseases have created significant opportunities for the market growth in the future. The slow growth of the introduction of new blockbuster drugs is a major concern which the drug development companies are catering to by using these top technologies.

Suven Life Sciences a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets in CNS disorders for unmet medical needs with $20 billion market potential, today announced that it is participating at 29th J.P. Morgan Healthcare Conference being held in San Francisco, USA during 10th to 13th Jan 2011. J.P. Morgan Healthcare conference is the premier conference of its kind, bringing together established industry leaders, emerging fast-growth companies, innovative technology creators and globally minded service providers who will deliver presentations to more than 4,000 investors. This conference puts you at the center of the investment and partnering community and provides an open format to connect with the funding partners. With the targeted audience of senior executives and industry leaders from pharmaceutical, biotechnology and venture capital communities, J.P. Morgan Healthcare Conference provides the greatest opportunity for relationship building, facilitating discussions on financing opportunities with an unparalleled opportunity to create new value generating partnerships. Mr.Venkat Jasti CEO of Suven is scheduled to discuss the company’s corporate overview, business strategy, fund raising and partnering activity for their Phase 2a ready clinical candidate SUVN-502 for cognition in Alzheimer’s and Schizophrenia at the J.P. Morgan Healthcare Conference 2011 where the world’s top notch investment professionals will present along with the most innovative companies who are decision makers. The Company has twelve (12) internally discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.


In a related development Imperial Innovations Group plc, the company that commercialises technologies and discoveries from Imperial College London, has today announced to the stock exchange a fundraising worth £140 million which will boost support to inventions inspired by research at the College. Making Imperial Innovations the UK’s largest company investing in university inventions, the funds will accelerate the number and size of investments that can be made to Imperial College London spin-out companies, thus enabling them to achieve their commercial goals more quickly. Imperial Innovations is the first and only university-owned commercialization company to be publicly listed. It supports academic staff at Imperial College London with the translation of their ideas and discoveries for the commercial market through licensing or establishing new companies. Since April 2005 a technology pipeline agreement has been in place, giving Imperial Innovations the right, subject to certain exceptions, to exploit and commercialize the College’s unencumbered intellectual property.